Oligonucleotides Carrying Nucleoside Antimetabolites as Potential Prodrugs

Background: Nucleoside and nucleobase antimetabolites are an important class of chemotherapeutic agents for the treatment of cancer as well as other diseases. Introduction: In order to avoid undesirable side effects, several prodrug strategies have been developed. In the present review, we describe...

Descripción completa

Detalles Bibliográficos
Autores: Fàbrega, Carme, Clua, Anna, Eritja Casadellà, Ramón, Aviñó, Anna
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2022
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:dnet:digitalcsic_::8833fc9cd223d2269e56fd67bce2d54d
Acceso en línea:http://hdl.handle.net/10261/266680
Access Level:acceso abierto
Palabra clave:Nucleoside Antimetabolites
Antimetabolites
cytarabine.
gemcitabine
floxuridine
id ES_6fa925e69e48cc99e810f4c4fb406f92
oai_identifier_str oai:dnet:digitalcsic_::8833fc9cd223d2269e56fd67bce2d54d
network_acronym_str ES
network_name_str España
repository_id_str
spelling Oligonucleotides Carrying Nucleoside Antimetabolites as Potential ProdrugsFàbrega, CarmeClua, AnnaEritja Casadellà, RamónAviñó, AnnaNucleoside AntimetabolitesAntimetabolitescytarabine.gemcitabinefloxuridineBackground: Nucleoside and nucleobase antimetabolites are an important class of chemotherapeutic agents for the treatment of cancer as well as other diseases. Introduction: In order to avoid undesirable side effects, several prodrug strategies have been developed. In the present review, we describe a relatively unknown strategy that consists of using oligonucleotides modified with nucleoside antimetabolites as prodrugs. Methods: The active nucleotides are generated by enzymatic degradation once incorporated into cells. This strategy has attracted large interest and is widely utilized at present due to the continuous developments made in therapeutic oligonucleotides and the recent advances in nanomaterials and nanomedicine. Results: A large research effort was made mainly in the improvement of the antiproliferative properties of nucleoside homopolymers, but recently, chemically modified aptamers, antisense oligonucleotides and/or siRNA carrying antiproliferative nucleotides have demonstrated a great potential due to the synergetic effect of both therapeutic entities. In addition, DNA nanostructures with interesting properties have been built to combine antimetabolites and enhancers of cellular uptake in the same scaffold. Finally, protein nanoparticles functionalized with receptor-binders and antiproliferative oligomers represent a new avenue for a more effective treatment in cancer therapy. Conclusion: It is expected that oligonucleotides carrying nucleoside antimetabolites will be considered as potential drugs in the near future for biomedical applications.Peer reviewedBentham Science PublishersEritja Casadellà, Ramón [0000-0001-5383-9334]Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202220222022info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Postprintinfo:eu-repo/semantics/acceptedVersionhttp://hdl.handle.net/10261/266680reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglés10.2174/0929867328666211129124039Síinfo:eu-repo/semantics/openAccessoai:dnet:digitalcsic_::8833fc9cd223d2269e56fd67bce2d54d2026-05-22T06:33:51Z
dc.title.none.fl_str_mv Oligonucleotides Carrying Nucleoside Antimetabolites as Potential Prodrugs
title Oligonucleotides Carrying Nucleoside Antimetabolites as Potential Prodrugs
spellingShingle Oligonucleotides Carrying Nucleoside Antimetabolites as Potential Prodrugs
Fàbrega, Carme
Nucleoside Antimetabolites
Antimetabolites
cytarabine.
gemcitabine
floxuridine
title_short Oligonucleotides Carrying Nucleoside Antimetabolites as Potential Prodrugs
title_full Oligonucleotides Carrying Nucleoside Antimetabolites as Potential Prodrugs
title_fullStr Oligonucleotides Carrying Nucleoside Antimetabolites as Potential Prodrugs
title_full_unstemmed Oligonucleotides Carrying Nucleoside Antimetabolites as Potential Prodrugs
title_sort Oligonucleotides Carrying Nucleoside Antimetabolites as Potential Prodrugs
dc.creator.none.fl_str_mv Fàbrega, Carme
Clua, Anna
Eritja Casadellà, Ramón
Aviñó, Anna
author Fàbrega, Carme
author_facet Fàbrega, Carme
Clua, Anna
Eritja Casadellà, Ramón
Aviñó, Anna
author_role author
author2 Clua, Anna
Eritja Casadellà, Ramón
Aviñó, Anna
author2_role author
author
author
dc.contributor.none.fl_str_mv Eritja Casadellà, Ramón [0000-0001-5383-9334]
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Nucleoside Antimetabolites
Antimetabolites
cytarabine.
gemcitabine
floxuridine
topic Nucleoside Antimetabolites
Antimetabolites
cytarabine.
gemcitabine
floxuridine
description Background: Nucleoside and nucleobase antimetabolites are an important class of chemotherapeutic agents for the treatment of cancer as well as other diseases. Introduction: In order to avoid undesirable side effects, several prodrug strategies have been developed. In the present review, we describe a relatively unknown strategy that consists of using oligonucleotides modified with nucleoside antimetabolites as prodrugs. Methods: The active nucleotides are generated by enzymatic degradation once incorporated into cells. This strategy has attracted large interest and is widely utilized at present due to the continuous developments made in therapeutic oligonucleotides and the recent advances in nanomaterials and nanomedicine. Results: A large research effort was made mainly in the improvement of the antiproliferative properties of nucleoside homopolymers, but recently, chemically modified aptamers, antisense oligonucleotides and/or siRNA carrying antiproliferative nucleotides have demonstrated a great potential due to the synergetic effect of both therapeutic entities. In addition, DNA nanostructures with interesting properties have been built to combine antimetabolites and enhancers of cellular uptake in the same scaffold. Finally, protein nanoparticles functionalized with receptor-binders and antiproliferative oligomers represent a new avenue for a more effective treatment in cancer therapy. Conclusion: It is expected that oligonucleotides carrying nucleoside antimetabolites will be considered as potential drugs in the near future for biomedical applications.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Postprint
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/266680
url http://hdl.handle.net/10261/266680
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv 10.2174/0929867328666211129124039
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Bentham Science Publishers
publisher.none.fl_str_mv Bentham Science Publishers
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410523963981825
score 15.812429

Similares en LA Referencia